Detalhe da pesquisa
1.
Report of the international conference on manufacturing and testing of pluripotent stem cells.
Biologicals
; 56: 67-83, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30150108
2.
A strategic road map to filing a Biologics License Application for a pluripotent stem cell derived therapeutic product.
Biologicals
; 59: 68-71, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31053443
3.
Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study.
Mol Pharm
; 9(5): 1100-8, 2012 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-22376012
4.
A stem cell journey in ophthalmology: From the bench to the clinic.
Stem Cells Transl Med
; 10(12): 1581-1587, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34515419
5.
A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia.
Crit Care
; 13(2): R36, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19284881
6.
CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges.
Cell Stem Cell
; 22(6): 801-805, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29859170
7.
Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME).
J Pharm Sci
; 96(11): 2957-69, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17705287
8.
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.
JAMA
; 290(2): 238-47, 2003 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-12851279